Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:IBRX NASDAQ:KOD NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$119.90+5.4%$117.38$5.59▼$148.83$9.06B0.84849,335 shs1.24 million shsIBRXImmunityBio$8.05+3.7%$7.77$1.95▼$12.43$8.13B0.0212.32 million shs24.75 million shsKODKodiak Sciences$36.22+5.2%$37.01$3.26▼$47.84$2.15B2.32615,107 shs665,331 shsKRYSKrystal Biotech$302.05+3.0%$270.39$122.80▼$319.48$8.65B0.5324,532 shs197,097 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+0.16%-6.31%-5.35%-10.43%+1,834.18%IBRXImmunityBio-3.00%-4.43%+0.78%-9.13%+177.14%KODKodiak Sciences-1.71%-12.84%-23.34%+40.03%+827.76%KRYSKrystal Biotech+0.53%-5.48%+6.96%+3.53%+121.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$119.90+5.4%$117.38$5.59▼$148.83$9.06B0.84849,335 shs1.24 million shsIBRXImmunityBio$8.05+3.7%$7.77$1.95▼$12.43$8.13B0.0212.32 million shs24.75 million shsKODKodiak Sciences$36.22+5.2%$37.01$3.26▼$47.84$2.15B2.32615,107 shs665,331 shsKRYSKrystal Biotech$302.05+3.0%$270.39$122.80▼$319.48$8.65B0.5324,532 shs197,097 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+0.16%-6.31%-5.35%-10.43%+1,834.18%IBRXImmunityBio-3.00%-4.43%+0.78%-9.13%+177.14%KODKodiak Sciences-1.71%-12.84%-23.34%+40.03%+827.76%KRYSKrystal Biotech+0.53%-5.48%+6.96%+3.53%+121.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.1514.39% UpsideIBRXImmunityBio 2.86Moderate Buy$14.2076.40% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1416.35% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.117.30% UpsideCurrent Analyst Ratings BreakdownLatest KOD, ABVX, KRYS, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.005/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/21/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/20/2026ABVXAbivax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026IBRXImmunityBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AIBRXImmunityBio$113.29M74.42N/AN/A($0.83) per share-9.70KODKodiak SciencesN/AN/AN/AN/A$1.79 per shareN/AKRYSKrystal Biotech$389.13M22.88$7.51 per share40.24$43.31 per share6.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)IBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%N/AKRYSKrystal Biotech$204.83M$7.4840.3828.71N/A53.92%19.25%17.62%8/3/2026 (Estimated)Latest KOD, ABVX, KRYS, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/25/2026Q1 2026ABVXAbivax-$0.9359N/AN/AN/A$0.40 millionN/A5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/A3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million2/23/2026Q4 2025IBRXImmunityBio-$0.08-$0.06+$0.02-$0.06N/A$38.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.758.75IBRXImmunityBioN/A6.676.66KODKodiak SciencesN/A3.543.54KRYSKrystal BiotechN/A9.469.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%IBRXImmunityBio8.58%KODKodiak Sciences89.06%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AIBRXImmunityBio69.48%KODKodiak Sciences45.90%KRYSKrystal Biotech13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.70 millionN/ANot OptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableKOD, ABVX, KRYS, and IBRX HeadlinesRecent News About These CompaniesTimesSquare Capital Management LLC Cuts Position in Krystal Biotech, Inc. $KRYSMay 20 at 6:56 AM | marketbeat.comAtle Fund Management AB Sells 8,338 Shares of Krystal Biotech, Inc. $KRYSMay 20 at 3:10 AM | marketbeat.comPittsburgh Biotech's Gene Gel Wins UK Green Light for DEB WoundsMay 19 at 1:10 PM | hoodline.comHKrystal Biotech gains regulatory approval to sell gene therapy in the United KingdomMay 19 at 1:10 PM | bizjournals.comKrystal Biotech's (KRYS) Buy Rating Reaffirmed at HC WainwrightMay 18 at 8:15 AM | marketbeat.comKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaMay 18 at 8:00 AM | globenewswire.comVIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Krystal Biotech, Inc. $KRYSMay 16, 2026 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16, 2026 | marketbeat.comKrystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThis Profitable Biotech Stealthily Climbs Into A Buy ZoneMay 11, 2026 | investors.comKrystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference UpdateMay 11, 2026 | finance.yahoo.comKrystal Biotech (NASDAQ:KRYS) Hits New 52-Week High - Here's WhyMay 11, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Reduces Stock Position in Krystal Biotech, Inc. $KRYSMay 11, 2026 | marketbeat.comKrystal Biotech: Vyjuvek Is Not The Primary AssetMay 10, 2026 | seekingalpha.comKrystal Biotech, Inc. $KRYS Shares Purchased by Principal Financial Group Inc.May 10, 2026 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Rating Increased to Buy at Wall Street ZenMay 9, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Krystal Biotech (KRYS), Twist Bioscience (TWST)May 8, 2026 | theglobeandmail.comGuggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)May 8, 2026 | theglobeandmail.comKrystal Biotech to Present at BofA Securities 2026 Health Care ConferenceMay 7, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Encompass Health (EHC)May 7, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026KOD, ABVX, KRYS, and IBRX Company DescriptionsAbivax NASDAQ:ABVX$119.90 +6.17 (+5.43%) Closing price 04:00 PM EasternExtended Trading$121.00 +1.10 (+0.92%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.ImmunityBio NASDAQ:IBRX$8.05 +0.29 (+3.74%) Closing price 04:00 PM EasternExtended Trading$8.05 +0.00 (+0.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kodiak Sciences NASDAQ:KOD$36.22 +1.80 (+5.23%) Closing price 04:00 PM EasternExtended Trading$35.81 -0.41 (-1.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Krystal Biotech NASDAQ:KRYS$302.05 +8.75 (+2.98%) Closing price 04:00 PM EasternExtended Trading$318.29 +16.24 (+5.38%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
